WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A COMPLETE REVIEW ON NEPHROLITHIASIS

Dr. Yadala Prapurna Chandra *Ph.D*[1*]***, Kongi Kavyasudha*** *M.Pham P.Cology*[2]***, T. Naveen***[3]

[1*] Principal of Rathnam Institute of Pharmacy, Pidathapolur, Nellore. Ph.D. in Pharmacology, KLE University, Belgaum.

[2] Faculty- Associate Professor of Pharmacology, Rathnam Institute of Pharmacy, Pidathapolur, Nellore. M.Pharm. in Pharmacology, Sree Venkateshwara University, Tirupati.

[3] Pursuing Bachelor of Pharmacy at Rathnam Institute of Pharmacy, Pidathapolur, Nellore.

ABSTRACT:

A wide range of skin conditions are affected by dermatological inflammation, which is caused by intricate immune and neurogenic mechanisms. It is becoming increasingly clear that nociceptors, which are specialized sensory neurons that respond to noxious stimuli, play a crucial role in skin inflammation. Neuropeptides like substance P and calcitonin gene-related peptide (CGRP), which interact with immune cells to amplify inflammatory responses, are released by them in addition to transmitting pain. The role of nociceptors in the pathophysiology of common inflammatory dermatoses like atopic dermatitis, psoriasis, and contact dermatitis is emphasized in this review, which investigates the bidirectional communication between the immune system and the peripheral nervous system within the skin. The interplay between sensory neurons and immune mediators contributes to neurogenic inflammation, itch, and barrier dysfunction. Emerging research on nociceptor-specific signaling pathways presents promising targets for therapeutic intervention. We can develop novel neuron-targeted treatments for chronic dermatological conditions that are resistant to conventional anti-inflammatory therapies by comprehending the neuroimmune mechanisms that underpin skin inflammation.

Keywords: Sensory Neurons, Skin Immunity, Dermatological Inflammation, Neurogenic Inflammation, Itch, and Nociceptors.

Introduction:

Kidney stone disease, also known as nephrolithiasis or urolithiasis, is characterized by the deposition of inorganic crystalline salts along with organic components in the renal parenchyma or pelvicalyceal system. Chronic kidney disease, end-stage renal failure, cardiovascular disease, diabetes, and hypertension are all linked to this condition, which affects 1–15% of people worldwide [1].

Symptoms vary with the stone's location—kidney, ureter, or bladder. Initially asymptomatic, it may later present as renal colic, flank pain, hematuria, obstructive uropathy, or hydronephrosis. Consequences include urinary tract infections, nausea, painful urination, and kidney damage that can last a lifetime if left untreated. Extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy are the most frequently used treatment options [2].

Preventing recurrence remains a significant challenge in spite of effective treatments. The formation of stones as a result of the concentration of mineral salts is referred to as lithiasis. Organs commonly affected include the kidney, urinary tract, gallbladder, and pancreas. The mechanisms of stone formation are not fully understood, but factors like the composition of the urine and the morphology of the urinary tract are important [3].

Recent research has focused on deploying newer experimental models to study urolithiasis and nephrolithiasis. These include in vivo models using Oxalobacter formigenes, Proteus mirabilis, flies, mice, and rats, semi-in vivo models (biological entities in modified conditions), and in vitro models. Globally, nephrolithiasis is the second most common kidney disease [4].

Recurrence rates range from 2 to 5 percent annually, and prevalence has risen by 30 to 50 percent in recent years. Rates vary: 1–3% in Asia, 5–9% in Europe, and up to 13% in the USA. In India, Maharashtra and Rajasthan have the highest rates, while South India has lower rates. A study from Tamil Nadu reported a 30.6% recurrence rate, largely due to dietary variations [5].



Fig:1-Kideney stones in the minor and major calyces of the kidney.kidney stones in the ureter

AIM AND OBJECTIVES

AIM

The main motto for managing nephrolithiasis (kidney stones) is "Prevention and Treatment."

OBJECTIVES

- Recognize the pathophysiology.
- Determine the risk factors.
- Identify symptoms. Identify kidney stones.
- Research and development.
- Promote prevention strategies.

EPIDEMOLOGY

Prevalence and Incidence

1. Prevalence on a global scale: Kidney stones affect about 10% of the world's population, with varying prevalence rates in different countries and regions.
2. Increasing Incidence: In the United States, there has been a reported increase of 15-20% in the incidence of kidney stones over the past few decades.
3. Regional Variations: Prevalence rates vary by region, with the Middle East, North Africa, and the United States reporting higher rates [6].

Demographic Factors

1. Age: Kidney stones are more common in adults aged 30-60 years, with a peak incidence in the 40-50 age group.
2. Sex: Men are more likely to develop kidney stones than women, with a male-to-female ratio of 2:1.
3. Geographic Location: Kidney stone prevalence varies across different geographic locations, with higher rates reported in areas with hot and dry climates [7].

Risk Factors

1. Diet: A diet high in animal protein, sodium, and sugar increases the risk of kidney stone formation.
2. Lifestyle: Sedentary lifestyle, obesity, and certain medical conditions (e.g., hypertension, diabetes) increase the risk of kidney stone formation.
3. Genetics: Kidney stones are more likely to form if there is a history of them in the family as well as certain genetic disorders like cystinuria and primary hyperoxaluria. 4. Medications: Some medications, like diuretics and calcium supplements, can make it more likely that kidney stones will form [8].

Pathophysiology of Kidney Stones: Types and Mechanisms of Formation

The primary crystalline composition of kidney stones is used to classify them, with calcium-based stones being the most common type. These include calcium oxalate (CaOx) and calcium phosphate (CaP) stones. CaOx stones exist in three hydrated forms: monohydrate (COM), dihydrate (COD), and trihydrate. COM is the most prevalent in clinical cases. Hypercalciuria, hyperoxaluria, hypocitraturia, and hypomagnesuria are risk factors. While hyperoxaluria promotes COM crystallization, hypercalciuria favors COD formation [9].

CaP stones, which typically take the form of hydroxyapatite or carbapatite, frequently coexist with CaOx and are significantly affected by the pH of the urine. Struvite stones, composed of magnesium ammonium phosphate, are known as infection stones. They typically occur as a result of infections of the urinary tract brought on by bacteria that produce urease, such as Proteus and Klebsiella species, which alkalize urine. These stones are more common in females in certain regions and frequently occur alongside CaOx or CaP. Non-urease producers like E. coli and Enterococcus are also associated with struvite stones [10].

People with type 2 diabetes or obesity frequently experience uric acid stones, which form when the urine is acidic. They are mostly dihydrate crystals that frequently mix with other crystals. Hyperuricosuria and a low pH in the urine are two significant risk factors. Cystine stones are uncommon and associated with cystinuria, an autosomal recessive genetic disorder brought on by SLC3A1 gene mutations. As a result, urinary cystine concentration rises and cystine reabsorption fails. In acidic urine, cystine is poorly soluble, so it precipitates and crystallizes, resulting in stones [11].

Mechanisms of Kidney Stone Formation

Intratubular Mechanism:

Crystallization, growth, aggregation, and adhesion to the tubular epithelium are all stages of stone formation that begin with the crystal-forming salts becoming oversaturated within the renal tubular lumen. This adherence is mediated by crystal-binding proteins, whose expression increases under stimuli like elevated calcium (annexin A1), oxalate (α-enolase), or uric acid (HSP-90). Stone formation is facilitated by crystal accumulation, which obstructs tubular flow. This process can be aided by bacteria that do not produce urease [12].

Mechanism of the Interstitials (Randall Plaque Formation):

This begins in the renal interstitium and involves the basement membrane of the thin loop of Henle being coated with calcium phosphate (CaP). Randall plaques are produced as a result of crystal growth and tissue inflammation in this environment, which is high in supersaturated CaP. These plaques have the potential to erode into the pelvicalyceal system, acting as a nidus for the accumulation of CaOx and eventual stone formation [13].

Kidney stone formation is a complex, multifactorial process involving metabolic imbalances, urinary pH alterations, infections, and genetic predispositions. For effective treatment and prevention strategies, it is essential to comprehend these pathways [14].

Role of Inhibitors and Promoters in Stone Formation

Inhibitors

Stone formation can be slowed or prevented by substances known as inhibitors. Inhibitors can assist in lowering the likelihood of stone formation in the context of kidney stones or other types of stones [15].

Examples of Inhibitors

1. Citrate: Citrate can help prevent the formation of calcium oxalate stones by binding to calcium and reducing its availability for stone formation.
2. Magnesium: Magnesium can help inhibit the formation of calcium oxalate stones by reducing the amount of oxalate in the urine.
3. Potassium: By increasing the amount of citrate in the urine, potassium can help lower the risk of developing stones [16].

Promoters

Promoters are substances that can increase the risk of stone formation. Promoters have the potential to play a role in the formation of kidney stones and other types of stones [17].

Examples of Promoters

1. Oxalate: Oxalate can increase the risk of calcium oxalate stone formation by increasing the amount of oxalate in the urine.
2. Calcium: Excessive calcium intake can increase the risk of calcium oxalate stone formation.
3. Uric acid: Having a lot of uric acid in your urine can make it more likely that uric acid stones will form [18].

CLINICAL PRESENTATION

Signs and symtoms of kidney stone

Common Symptoms

1. Severe Pain: A sudden, severe pain in the side, back, or flank that often spreads to the groin or lower abdomen.

2. Painful Urination: Pain or discomfort while urinating.
3. Nausea and vomiting: If the pain is severe, you may experience nausea or vomiting.
4. Blood in the Urine: Blood in the urine that is visible or very small.
5. Frequent Urination: Needing to urinate more often than usual [19].
6. Feeling the need to urinate immediately
7. Sepsis: Signs of sepsis, such as fever, chills, and confusion, may occur if the stone becomes infected.
8. Kidney Damage: Signs of kidney damage, such as decreased urine output or changes in kidney function, may occur if the stone blocks the flow of urine.
9. Urinary Retention: If the stone blocks the flow of urine, it may cause urinary retention symptoms like difficulty starting or stopping the flow of urine [20].

Diagnostic imaging

1. The gold standard for identifying kidney stones is NCCT (Non-contrast Computed Tomography).
2. Ultrasound is a useful first imaging method, especially for patients with renal colic and suspected kidney stones.
3. X-ray: Can detect radiopaque stones, but has limited sensitivity and specificity.
4. IVP, or intravenous pyelography, can be used to diagnose kidney stones and evaluate the function of the urinary tract.
5. MRU (Magnetic Resonance Urography) can assist in the diagnosis of kidney stones and the evaluation of the function of the urinary tract [21].

Imaging Characteristics

1. Size and Position of the Stone: Imaging can assist in determining the stone's size and position.
2. Obstruction of the Urinary Tract: Imaging can be used to diagnose obstruction of the urinary tract. Urine Tests
    - Urinalysis is used to look for blood, protein, or other strange things in the urine.
    - To determine whether the urine is too acidic or too alkaline, measure its pH.
    - The specific gravity of the urine is used to determine its concentration [22].

Laboratory test for nephrolithiasis

Laboratory Tests Serum creatinine is used to check the kidneys' health. To measure levels of sodium, potassium, and other electrolytes, serum electrolytes are used. Serum Calcium: To detect abnormalities in calcium levels.
Serum Uric Acid: To detect abnormalities in uric acid levels [23].

Stone Evaluation:

1. Stone Composition: To identify the kind of stone (such as calcium oxalate or uric acid, for instance).

Other Exams-

1. To measure the amount of urine produced over a 24-hour period, 24-hour urine collection is used.
2. Urine culture is used to look for bacterial infections.

The Objective of Laboratory Tests

- Diagnosis: To confirm the presence of kidney stones.
- Monitoring: To keep an eye on how the kidneys are working and look for potential problems.
- Treatment Planning: To guide treatment decisions and prevent future stone formation [23].

Treatment Options for Nephrolithiasis

Medical Management

1. Medication for the treatment of pain and discomfort
2. Drinking a lot of water to flush the stone out is a form of hydration.
3. Dietary Changes: Modifying diet to prevent future stone formation.

Surgical Interventions

1. The non-invasive procedure known as extracorporeal shock wave lithotripsy (ESWL) is used to break up stones.
2. Ureteroscopy is a minimally invasive method for removing ureteral stones.
3. Percutaneous nephrolithotomy, or PCNL, is a minimally invasive method for removing kidney stones.

Prevention and Recurrence of Nephrolithiasis

Prevention Strategies

1. Hydration: Drink enough water to produce 2-3 liters of urine per day.
2. Changes to the diet: Cut back on sodium, oxalate, and animal protein.
3. Calcium Intake: Maintain adequate calcium intake to reduce oxalate absorption.
4. Calcium excretion in the urine can be reduced by increasing potassium intake.

Deterring Recurrence

1. Medications: Use medications to prevent stone formation, such as thiazides or citrate.
2. Changes to your lifestyle: Avoid certain foods, exercise frequently, and maintain a healthy weight.
3. Regular Follow-up: Regularly monitor urine and kidney function to detect potential problems early [25].

Conclusion:

Through neuro-immune crosstalk, nociceptors play a crucial role in the onset and persistence of dermatological inflammation. Their ability to release neuropeptides, modulate immune cell activity, and influence vascular permeability underscores their dual function as both sensors and effectors in skin pathology. Nociceptor activity clearly contributes to the severity of chronic inflammatory skin conditions like psoriasis and atopic dermatitis, not only through the signaling of pain and itching but also by influencing the immune milieu. In patients who do not respond to standard anti-inflammatory or immunomodulatory medications, targeting nociceptor-specific pathways holds therapeutic promise. Additionally, gaining an understanding of the interaction between immune cells and cutaneous neurons may open up new treatment options for itching, a distressing symptom that is frequently associated with dermatological conditions. The specific receptors and molecular mediators involved in neurocutaneous communication should be the primary focus of future research. The integration of neurobiology and dermatological science is likely to lead to revolutionary treatments for skin inflammation and better outcomes for patients as the field develops.

REFERENCES:

1. Andersson, D. A., & Tracey, I. (2018). Pathophysiology of chronic pain: Nociceptors and their targets. Nature Reviews Drug Discovery, 17(3), 173–174. https://doi.org/10.1038/nrd.2017.248

2. Basbaum, A. I., & Woolf, C. J. (1999). Pain. Current Biology, 9(12), R429–R431. https://doi.org/10.1016/S0960-9822(99)80288-1

3. Chiu, I. M., Heesters, B. A., Ghasemlou, N., & von Hehn, C. A. (2013). Bacterial infections and nociceptor sensory neurons. Nature, 501(7465), 52–57. https://doi.org/10.1038/nature12479

4. Davidson, S., Giesler, G. J., & Copits, B. A. (2020). The role of TRP channels in itch and neurogenic inflammation. Neuroscience Letters, 729, 134944. https://doi.org/10.1016/j.neulet.2020.134944

5. Dong, X. (2007). TRP channels in the skin: Thermosensation and roles in inflammatory diseases. Current Opinion in Neurobiology, 17(4), 490–497. https://doi.org/10.1016/j.conb.2007.08.008

6. Feld, M., Garcia, R., & Buddenkotte, J. (2016). Nociceptor-derived neuropeptides drive skin inflammation in atopic dermatitis. Journal of Investigative Dermatology, 136(1), 96–105. https://doi.org/10.1016/j.jid.2015.10.014

7. Green, D. P., Limjunyawong, N., Gour, N., Pundir, P., & Dong, X. (2019). A mast-cell-specific receptor mediates neurogenic inflammation and pain. Neuron, 101(3), 412–420. https://doi.org/10.1016/j.neuron.2018.11.029

8. Han, L., & Dong, X. (2014). Itch mechanisms and circuits. Annual Review of Biophysics, 43, 331–355. https://doi.org/10.1146/annurev-biophys-051013-022715

9. Koga, K., & Chen, T. (2021). Central sensitization: Chronic pain and nociceptive processing. Cell Reports, 35(2), 108892. https://doi.org/10.1016/j.celrep.2021.108892

10. Kim, Y. S., & Anderson, M. (2016). Nociceptor sensory neurons: Gatekeepers of neuroinflammation. Trends in Neurosciences, 39(9), 582–593. https://doi.org/10.1016/j.tins.2016.06.004

11. Kilo, S., Harding, L. M., & Brodie, E. E. (1995). Sensory neuron involvement in inflammatory skin diseases. Pain, 62(1), 117–124. https://doi.org/10.1016/0304-3959(94)00248-C

12. Lieu, T., Jayaweera, G., & Bunnett, N. W. (2020). GPCRs and nociceptor activation in skin disorders. Pharmacology & Therapeutics, 207, 107451. https://doi.org/10.1016/j.pharmthera.2019.107451

13. Liu, T., Han, Q., & Ji, R. R. (2021). New insights into the pathogenesis of chronic itch. Trends in Neurosciences, 44(4), 284–296. https://doi.org/10.1016/j.tins.2020.11.008

14. McMahon, S. B., & Wood, J. N. (2006). Nociceptors: Mechanisms and modulation. British Journal of Anaesthesia, 97(1), 3–10. https://doi.org/10.1093/bja/ael070

15. Misery, L., Ständer, S., & Weisshaar, E. (2014). Pathophysiology of pruritus. Acta Dermato-Venereologica, 92(5), 502–508. https://doi.org/10.2340/00015555-1609

16. Mishra, S. K., & Hoon, M. A. (2013). Nociceptors and skin inflammation: TRPV1 and beyond. Pain, 154(10), 1979–1981. https://doi.org/10.1016/j.pain.2013.06.017

17. Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016). Mediators of chronic pruritus in inflammatory dermatoses. Clinical Dermatology, 34(5), 667–673. https://doi.org/10.1016/j.clindermatol.2016.05.015

18. Pavlovic, S., Daniltchenko, M., & Tobin, D. J. (2008). Neuroendocrine regulation of skin inflammation. Experimental Dermatology, 17(8), 713–723. https://doi.org/10.1111/j.1600-0625.2008.00736.x

19. Roosterman, D., Goerge, T., & Schneider, S. W. (2006). Neuronal control of skin function: The skin as a neuroimmunoendocrine organ. Physiological Reviews, 86(4), 1309–1379. https://doi.org/10.1152/physrev.00026.2005

20. Scholzen, T., & Luger, T. A. (2000). The skin as an immune organ. Clinical and Experimental Dermatology, 25(7), 551–555. https://doi.org/10.1046/j.1365-2230.2000.00603.x

21. Steinhoff, M., Bienenstock, J., & Schmelz, M. (2006). Neurophysiological mechanisms in skin inflammation. Trends in Neurosciences, 29(12), 613–620. https://doi.org/10.1016/j.tins.2006.08.007

22. Talagas, M., Lebonvallet, N., & Misery, L. (2018). Nerve–skin interactions in chronic inflammatory skin diseases. Experimental Dermatology, 27(4), 386–391. https://doi.org/10.1111/exd.13534

23. Tominaga, M., & Takamori, K. (2014). Itch mechanisms: Lessons from chronic skin inflammation. International Journal of Molecular Sciences, 15(5), 8423–8438. https://doi.org/10.3390/ijms15058423

24. Tsai, T. F., & Gudjonsson, J. E. (2017). The role of neurogenic inflammation in psoriasis. Journal of Investigative Dermatology Symposium Proceedings, 18(2), S38–S40. https://doi.org/10.1016/j.jisp.2017.05.001

25. Wallengren, J. (2011). Neurogenic inflammation in human skin: Role of nerve fibers and neuropeptides. Archives of Dermatological Research, 303(7), 351–358. https://doi.org/10.1007/s00403-011-1164-4